bluuebunny/crossref_metadata_2025_split huggingface dataset:
Assessing the effect of hyperbaric oxygen therapy in breast cancer patients with late radiation toxicity (HONEY trial): a trial protocol using a trial within a cohort design
Authors: Batenburg M. C. T. , van den Bongard H. J. G. D. , Kleynen C. E. , Maarse W. , Witkamp A. , Ernst M. , Doeksen A. , van Dalen T. , Sier M. , Schoenmaeckers E. J. P. , Baas I. O. , Verkooijen H. M. 
Published: November 2020

Abstract
Background
Breast cancer treatment with radiotherapy can induce late radiation toxicity, characterized by pain, fibrosis, edema, impaired arm mobility, and poor cosmetic outcome. Hyperbaric oxygen therapy (HBOT) has been proposed as treatment for late radiation toxicity; however, high-level evidence of effectiveness is lacking. As HBOT is standard treatment and reimbursed by insurers, performing classic randomized controlled trials is difficult. The “Hyperbaric OxygeN therapy on brEast cancer patients with late radiation toxicity” (HONEY) trial aims to evaluate the effectiveness of HBOT on late radiation toxicity in breast cancer patients using the trial within cohorts (TwiCs) design.

Methods
The HONEY trial will be conducted within the Utrecht cohort for Multiple BREast cancer intervention studies and Long-term evaluation (UMBRELLA). Within UMBRELLA, breast cancer patients referred for radiotherapy to the University Medical Centre Utrecht are eligible for inclusion. Patients consent to collection of clinical data and patient-reported outcomes and provide broad consent for randomization into future intervention studies. Patients who meet the HONEY in- and exclusion criteria (participation ≥ 12 months in UMBRELLA, moderate/severe breast or chest wall pain, completed primary breast cancer treatment except hormonal treatment, no prior treatment with HBOT, no contraindications for HBOT, no clinical signs of metastatic or recurrent disease) will be randomized to HBOT or control group on a 2:1 ratio (n = 120). Patients in the control group will not be informed about participation in the trial. Patients in the intervention arm will undergo 30–40 HBOT treatment sessions in a high pressure chamber (2.4 atmospheres absolute) where they inhale 100% oxygen through a mask. Cohort outcome measures (i.e., physical outcomes, quality of life, fatigue, and cosmetic satisfaction) of the HBOT group will be compared to the control group at 3 months follow-up.

Discussion
This pragmatic trial within the UMBELLA cohort was designed to evaluate the effectiveness of HBOT on late radiation toxicity in breast cancer patients using the TwiCs design. Use of the TwiCs design is expected to address issues encountered in classic randomized controlled trials, such as contamination (i.e., HBOT in the control group) and disappointment bias, and generate information about acceptability of HBOT.

Trial registration
ClinicalTrials.gov. NCT04193722. Registered on 10 December 2019.
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial
Authors: Devos Timothy , Geukens Tatjana , Schauwvlieghe Alexander , Ariën Kevin K. , Barbezange Cyril , Cleeren Myriam , Compernolle Veerle , Dauby Nicolas , Desmecht Daniël , Grimaldi David , Lambrecht Bart N. , Luyten Anne , Maes Piet , Moutschen Michel , Romano Marta , Seyler Lucie , Nevessignsky Michel Toungouz , Vandenberghe Katleen , van Griensven Johan , Verbeke Geert , Vlieghe Erika , Yombi Jean Cyr , Liesenborghs Laurens , Verhamme Peter , Meyfroidt Geert 
Published: November 2020

Abstract
Background
The COVID-19 pandemic has imposed an enormous burden on health care systems around the world. In the past, the administration of convalescent plasma of patients having recovered from SARS and severe influenza to patients actively having the disease showed promising effects on mortality and appeared safe. Whether or not this also holds true for the novel SARS-CoV-2 virus is currently unknown.

Methods
DAWn-Plasma is a multicentre nation-wide, randomized, open-label, phase II proof-of-concept clinical trial, evaluating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19 in Belgium. Patients hospitalized with a confirmed diagnosis of COVID-19 are eligible when they are symptomatic (i.e. clinical or radiological signs) and have been diagnosed with COVID-19 in the 72 h before study inclusion through a PCR (nasal/nasopharyngeal swab or bronchoalveolar lavage) or a chest-CT scan showing features compatible with COVID-19 in the absence of an alternative diagnosis. Patients are randomized in a 2:1 ratio to either standard of care and convalescent plasma (active treatment group) or standard of care only. The active treatment group receives 2 units of 200 to 250 mL of convalescent plasma within 12 h after randomization, with a second administration of 2 units 24 to 36 h after ending the first administration. The trial aims to include 483 patients and will recruit from 25 centres across Belgium. The primary endpoint is the proportion of patients that require mechanical ventilation or have died at day 15. The main secondary endpoints are clinical status on day 15 and day 30 after randomization, as defined by the WHO Progression 10-point ordinal scale, and safety of the administration of convalescent plasma.

Discussion
This trial will either provide support or discourage the use of convalescent plasma as an early intervention for the treatment of hospitalized patients with COVID-19 infection.

Trial registration
ClinicalTrials.govNCT04429854. Registered on 12 June 2020 - Retrospectively registered.
Complex cytogenetic abnormalities in chronic myeloid leukemia resulting in early progression to blast crisis: a case report
Authors: Malakzai Haider Ali , Rahmani Soma , Haidary Ahmed Maseh , Noor Sarah , Ahmad Maryam , Ibrahimkhil Abdul Sami , Sharif Samuel 
Published: November 2020

Abstract
Introduction
BCR-ABL1, resulting from t(9;22), is the oncogenic driver of chronic myeloid leukemia and the therapeutic target of the disease. Molecular studies have been the gold standard modality for patient assessment since the advent of tyrosine kinase inhibitor therapy. In spite of that, there are cytogenetic abnormalities that can render the disease unresponsive to conventional therapy, thus making cytogenetics an important component of patient management guidelines.

Case presentation
We present a case of a Tajik, Afghan patient with chronic myeloid leukemia with del(6)(q23.3q27), t(9;22)(q34;q11.2), monosomy 11, monosomy 12, and marker chromosome who, despite having typical clinical and hematological disease with initial response to therapy, progressed to blast crisis very early and thus required special interventions.

Conclusion
Cytogenetic monitoring is an important pillar in the management of patients with chronic myeloid leukemia that cannot be ignored. It should therefore be a part of patient management not only during diagnosis but also during management. We present an unusual cytogenetic abnormality in a patient with chronic myeloid leukemia that resulted in early disease progression.
Tetraspanin CD82 is necessary for muscle stem cell activation and supports dystrophic muscle function
Authors: Hall Arielle , Fontelonga Tatiana , Wright Alec , Bugda Gwilt Katlynn , Widrick Jeffrey , Pasut Alessandra , Villa Francesco , Miranti Cynthia K. , Gibbs Devin , Jiang Evan , Meng Hui , Lawlor Michael W. , Gussoni Emanuela 
Published: November 2020

Abstract
Background
Tetraspanins are a family of proteins known to assemble protein complexes at the cell membrane. They are thought to play diverse cellular functions in tissues by modifying protein-binding partners, thus bringing complexity and diversity in their regulatory networks. Previously, we identified the tetraspanin KAI/CD82 as a prospective marker for human muscle stem cells. CD82 expression appeared decreased in human Duchenne muscular dystrophy (DMD) muscle, suggesting a functional link to muscular dystrophy, yet whether this decrease is a consequence of dystrophic pathology or a compensatory mechanism in an attempt to rescue muscle from degeneration is currently unknown.

Methods
We studied the consequences of loss of CD82 expression in normal and dystrophic skeletal muscle and examined the dysregulation of downstream functions in mice aged up to 1 year.

Results
Expression of CD82 is important to sustain satellite cell activation, as in its absence there is decreased cell proliferation and less efficient repair of injured muscle. Loss of CD82 in dystrophic muscle leads to a worsened phenotype compared to control dystrophic mice, with decreased pulmonary function, myofiber size, and muscle strength. Mechanistically, decreased myofiber size in CD82−/− dystrophic mice is not due to altered PTEN/AKT signaling, although increased phosphorylation of mTOR at Ser2448 was observed.

Conclusion
Basal CD82 expression is important to dystrophic muscle, as its loss leads to significantly weakened myofibers and impaired muscle function, accompanied by decreased satellite cell activity that is unable to protect and repair myofiber damage.
Anticancer activities of cyclohexenone derivatives
Authors: Shin Soon Young , Park Jihyun , Jung Yearam , Lee Young Han , Koh Dongsoo , Yoon Youngdae , Lim Yoongho 
Published: November 2020

AbstractWe designed 21 ethyl 3,5-diphenyl-2-cyclohexenone-6-carboxylate derivatives to identify compounds exhibiting anticancer activity. To measure the inhibitory effects of the compounds on cancer cell growth, a long-term survival clonogenic assay was performed. Since compounds containing a cyclohexenone moiety inhibit the enzyme acetylcholinesterase, an in vitro acetylcholinesterase assay was performed for all 21 cyclohexenone derivatives. To examine the effect of the derivative that exhibited the best cancer cell growth inhibition on the induction of apoptosis by demonstrating the activation of caspases and apoptosis regulatory proteins, immunoblotting and immunofluorescence microscopic analyses were performed. The binding mode between the cyclohexenone derivatives and acetylcholinesterase was elucidated at the molecular level using in silico docking. Druggability was evaluated based on ligand efficiency.
Enset-based land use land cover change detection and its impact on soil erosion in Meki river watershed, Western Lake Ziway Sub-Basin, Central Rift Valley of Ethiopia
Authors: Woldesenbet Alemu Beyene , Wudmatas Sebsebe Demisew , Denboba Mekuria Argaw , Gebremariam Azage Gebreyohannes 
Published: November 2020

Abstract
Background
Water erosion, upland degradation and deforestation are key environmental problems in the Meki river watershed. The study assessed the land use land cover change (LULCC) for 30 years and it examined the contribution of indigenous Enset-based land use system (EBLUS) to reduce soil erosion and prevent water bodies including Lake Ziway from sedimentation which was not considered in the former studies. GPS based data collected and satellite based LULC analysis using ERDAS Imagine 2014 performed to investigate existing farm management practices and land cover respectively. HEC-GEOHMS, Geo-statistical interpolation and RUSLE were applied to model watershed characteristics, spatial climate parameters and soil loss respectively.

Result
Meki river watershed (2110.4 km2 of area) is dominantly covered by cultivated LUS (41.5%), EBLUS (10.65%), Bush and Chat LUS (25.6%), Forest and plantations LUS (14.14%), built-up (7.4%) and water bodies (0.75%). Soil loss is increasing from 1987 to 2017 and a larger part of the watershed suffers a moderately severe to very severe risk (18 t ha−1 year−1 to > 80 t ha−1 year−1) in all sub-watersheds irrespective of the land use systems which shows the watershed is facing sever degradation problem. The mean soil loss of 30.5 t ha−1 year−13 and 31.905 t ha−1 year−1 are verified from Enset growing zones and non-Enset growing zones of the watershed respectively.

Conclusion
EBLUS saves significant amount of soil despite the steepness of the slopes of the Enset growing zones of the watershed. Hence, expansion of EBLUS can contribute in sustaining water bodies, including Lake Ziway by reducing soil loss rate and sedimentation problem for the ecological sustainability of the watershed. Therefore, separate land use policy and awareness creation are mandatory for such EBLUS expansion, sustainable watershed management interventions and conservation of the natural environment in the watershed based on its suitability and severity of erosion risk mapping.
Weak bus-constrained PMU placement for complete observability of a connected power network considering voltage stability indices
Authors: Babu Rohit , Raj Saurav , Bhattacharyya Biplab 
Published: November 2020

AbstractPhasor measurement units (PMUs) are preferred for installation at weak buses in a power network. Therefore, the weak buses need to be located and the strategic locations of PMUs identified to ensure network observability. Thus, the primary aim of this work is to identify the placements of the maximum number of PMUs installed at the weak buses in the electrical network. The voltage collapse proximity indicator, line stability index, fast voltage stability index, and a new voltage stability indicator utilizing load flow measurement are used to determine the weak buses. A novel deterministic methodology based on a binary-integer linear programming model is then proposed to determine the optimal locations of PMUs. The effect of a single PMU outage considering the weak buses is also demonstrated. The effectiveness of the developed approach is tested and validated on the standard IEEE 14-, 118-, 300-, and New England 39-bus systems. The obtained results are also compared to those using different weak bus methodologies.
Genotype association of IP6K3 gene with Hashimoto’s thyroiditis in Algerian population (Aures region)
Authors: Kherrour Warda , Kalicanin Dean , Brčić Luka , Hambaba Leila , Yahia Mouloud , Benbia Souheyla , Perica Vesna Boraska 
Published: November 2020

Abstract
Background
Hashimoto’s thyroiditis (HT) is a chronic autoimmune disease of the thyroid gland and is also the main cause of hypothyroidism. A recent genome-wide association study (GWAS) suggested an association of three novel genetic variants with HT in a population of Caucasian origin (Croatian). A case-control study was performed to investigate the association of these three newly suggested genetic variants with HT in a non-Caucasian ethnic group, an Arab-Berber from Algeria.
Three variants (rs12944194 located 206 kb from SDK2, rs791903 inside IP6K3, and rs75201096 inside GNA14) were genotyped using real-time PCR.

Results
There were no significant differences in allele frequencies of the three genetic variants between HT cases and controls. However, the present study showed nominal significance in the genotype distribution of rs791903 (IP6K3 gene) between HT patients and the control group (P = 0.024); we observed a decrease in the frequency of rs791903 recessive homozygotes (CC) in HT cases versus controls (OR = 0.476, P = 0.025).

Conclusion
This is the first study that showed the genotypic association of IP6K3 intronic variant with decreased risk for HT in non-Caucasian, Algerian, population, whereas we did not confirm the association of SDK2 and GNA14 genetic variants with HT. The IP6K3 gene (inositol hexaphosphate kinase 3), located near major histocompatibility complex (MHC), has previously been associated with other common autoimmune diseases beside HT, such as Graves’s disease and rheumatoid arthritis, which is providing more evidence of a good candidacy for the genetic contribution to the development of HT and autoimmunity.
Chemical constituents, antioxidant, and antimicrobial activity of Allium chinense G. Don
Authors: Rhetso Thejanuo , Shubharani R. , Roopa M. S. , Sivaram V. 
Published: November 2020

Abstract
Background
Allium chinense G. Don is a medicinal and aromatic herb belonging to the family Amaryllidaceae, characterized by a high saponin content. The previous report has mostly been focused on the bulb, and there is very limited work on the leaf. The information about biological and chemical constituent of A. chinense leaf is still inadequate in contrast to the investigations reported on the bulb. To the best of our knowledge, there is no report on the hexane extract of both bulb and leaf extract. Therefore, the present investigation was focused on identifying and characterization of the hexane extracts of A. chinense bulb and leaf quantitatively and by using the GC-MS method and to know its scavenging, antibacterial, and antifungal activity.

Results
Twenty-eight bioactive compounds were identified in the bulb and nine in the leaf extract by GC-MS analysis. The versatile compounds present in the bulb are 2-methyloctacosane (21.30%), tetracontane (14.05%), eicosane, 10-methyl (12.06%), heneicosane (8.46%), octadecyl trifluoroacetate (6.48%), and 1-heneicosanol (5.76%), whereas in the leaf, it was phytol (35.76%), tetratetracontane (18.49%), perhydrofarnesyl acetone (14.76%), and heptadecane, 2,6-dimethyl (10.79%). In quantitative estimation, saponins were estimated to have the highest with 375.000 ± 0.577 mg/g in the leaf and 163.750 ± 0.433 mg/g in the bulb. The DPPH antioxidant scavenging activity was found to be minimum in both the bulb (IC50 = 678.347 μg/ml) and leaf (IC50 = 533.337 μg/ml). A. chinense extracts of both leaf and bulb exerted potential antibacterial effects against Staphylococcus aureus and Pseudomonas aeruginosa. Leaf extract exhibited greater antifungal activity than the bulb against Aspergillus niger.

Conclusion
From the analysis, the hexane leaf extract exhibited higher antibacterial, antifungal, and antioxidant activity than the bulb. Their superior activity might be due to the higher content of total saponin and terpenes. This result will lead to further in-depth research towards the potential use of this plant; the bio-constituents can be further isolated and used in medical and therapeutic applications.
Trajectories of Body Weight and Fat Mass in Relation to Incident Prediabetes in a Biracial Cohort of Free-Living Adults
Authors: Al Hommos Nisreen Abu , Ebenibo Sotonte , Edeoga Chimaroke , Dagogo-Jack Sam 
Published: November 2020

Abstract

Objectives
Obesity is a risk factor for type 2 diabetes (T2D), but prospective data relating adiposity measures to incident prediabetes are scant.

Methods
The Pathobiology of Prediabetes in A Biracial Cohort study followed normoglycemic African Americans (AA) and European Americans (EA) with parental history of T2D for the primary outcome of incident prediabetes (impaired fasting glucose and/or impaired glucose tolerance) for 5.5 years. Serial assessments included anthropometry and body fat composition. We analyzed weight, body mass index (BMI), waist, total, and abdominal fat mass in relation to incident prediabetes risk.

Results
Of the 376 subjects enrolled (217 AA, 159 EA; mean age 44.2 years, BMI 31.4 kg/m2), 343 (192 AA, 151 EA) had evaluable follow-up data. A total of 101 (52 AA, 49 EA) developed prediabetes during follow-up. Progressors to prediabetes had a mean baseline weight of 90.0 ± 20.4 kg versus 82.9 ± 21.7 kg among nonprogressors (P = 0.0036). During 5.5 (mean 2.62) years of follow-up, the weight change among nonprogressors was 0.63 ± 6.11 kg compared with 2.54 ± 6.91 kg among progressors (ANOVA P = 0.0072). Progressors also showed greater increases in total fat (P = 0.0015) and trunk fat (P = 0.0005) mass than nonprogressors. Adjusted for age and sex, the significant predictors of incident prediabetes were BMI (P = 0.0013), waist (P &lt; 0.0001), total fat (P = 0.0025), and trunk fat (P &lt; 0.0001) mass.

Conclusions
Among obese free-living offspring of parents with T2D, long-term normoglycemic status was associated with a weight gain of ~0.2 kg/y, whereas progression to prediabetes was associated with a weight gain of ~1 kg/y.
EM BUSCA DA IDENTIDADE EUROPEIA PERDIDA
Authors: Caetano João Carlos Relvão 
Published: November 2020

Objetivo: O presente ensaio tem como propósito verificar se existe ou não uma identidade europeia e quais são os seus elementos caracterizadores, procurando ainda perceber as consequências de tal facto para a Europa – de um modo particular para a União Europeia – e para o mundo.Metodologia: Trata-se de uma investigação interdisciplinar de natureza histórica, filosófica, política, cultural e jurídica que se socorre de uma metodologia dedutiva de análise documental visando à articulação de conhecimentos diversos. A articulação é possível pela definição de uma matriz de conhecimentos segundo uma perspetiva holística.Resultados: Comprova-se a existência de diferentes perspetivas sobre a identidade europeia, a qual se mostra essencial para a compreensão dos processos políticos e sociais na Europa. Evidencia-se ainda a necessidade de existir um entendimento mínimo entre os agentes políticos e os cidadãos sobre o que é a identidade europeia, a fim de que o projeto de construção europeia possa subsistir.Contribuições: A principal contribuição desta investigação consiste em mostrar que o processo de integração europeia não é simplesmente técnico, mas político. Sendo político, exige que se repense o processo de exercício do poder, tanto na União Europeia como nos Estados, substituindo a lógica clássica do poder pelo poder por uma lógica próxima dos cidadãos.
The relative incidence of COVID-19 in healthcare workers versus non-healthcare workers: evidence from a web-based survey of Facebook users in the United States
Authors: Flaxman Abraham D. , Henning Daniel J. , Duber Herbert C. 
Published: November 2020

Background: Healthcare workers are at the forefront of the COVID-19 pandemic and it is essential to monitor the relative infection rate of this group, as compared to workers in other occupations. This study aimed to produce estimates of the relative incidence ratio between healthcare workers and workers in non-healthcare occupations. Methods: Analysis of cross-sectional data from a daily, web-based survey of 1,788,795 Facebook users from September 6, 2020 to October 18, 2020. Participants were Facebook users in the United States aged 18 and above who were tested for COVID-19 because of an employer or school requirement in the past 14 days. The exposure variable was a self-reported history of working in healthcare in the past four weeks and the main outcome was a self-reported positive test for COVID-19. Results: On October 18, 2020, in the United States, there was a relative COVID-19 incidence ratio of 0.7 (95% UI 0.6 to 0.8) between healthcare workers and workers in non-healthcare occupations. Conclusions: Currently in the United States, healthcare workers have a substantially and significantly lower COVID-19 incidence rate than workers in non-healthcare occupations.